Drug Trial Radar · NCT06049147
Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jul 7, 2021
Primary completion
Aug 24, 2023
Study completion Aug 24, 2023
Sponsor
- Lead sponsor
- Medibiofarma S.L.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, randomised, double blind, placebo controlled clinical study to assess the safety and tolerability of MBF-015 in healthy volunteers.This clinical phase I trial is divided in two stages and involves, first, a single ascending dose (SAD) study in healthy young male volunteers and then a multiple ascending dose (MAD) study in healthy young men and woman. MBF-118 is developed for the treatment of multiple sclerosis.
Conditions
- Safety and Pharmacokinetic
Interventions
MBF-015 4 mg oral capsuleDrug
MBF-015 oral capsules Histone deacetylase inhibitor
MBF-015 16 mg oral capsuleDrug
MBF-015 oral capsules Histone deacetylase inhibitor
PlaceboDrug
Hard gelatin capsules filled with cellulose microcrystalline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse eventsTime frame: Day 1 through Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CIM-Sant Pau Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.